Novo Nordisk stock gains ~3.5% as oral Wegovy launches in UAE, Goldman Sachs raises price target, and investors await ADA conference updates on next-gen obesity treatments.<\/p>\n
Novo Nordisk shares recouped some ground on Thursday as a dense cluster of corporate catalysts \u2014 from the first international launch of its oral Wegovy pill to a slate of scientific presentations at the American Diabetes Association\u2019s annual meeting \u2014 drew buyers back into the stock. The Danish drugmaker closed the session between EUR 37.59 and EUR 37.67, a gain of roughly 3.3% to 3.5%, depending on the data feed. The move pushed the equity roughly 5% to 5.5% above its 50-day moving average, a modest technical victory after a punishing stretch that has left the share price nearly 46% below the 52-week high of EUR 70.13 set last June.<\/p>\n
The most tangible near-term catalyst came from outside the conference halls. Novo Nordisk has taken its oral formulation of semaglutide \u2014 sold as Wegovy \u2014 to the United Arab Emirates, its first market outside the United States. The company cited local demand and the region\u2019s existing healthcare infrastructure as drivers of the choice. The pill\u2019s efficacy, drawn from the OASIS-4 study, showed that consistent users shed roughly 17% of their body weight. Additional markets are expected in the second half of 2026, though specific countries have not been disclosed. The move comes as U.S. pharmacy benefit managers have expanded coverage of competing GLP-1 products, pressuring Novo to diversify geographically.<\/p>\n
Goldman Sachs analyst James Quigley responded to the strong early prescription data for the oral pill by lifting his price target on Novo Nordisk shares to DKK 305 from DKK 263, while maintaining a Neutral rating. The drug accumulated 1.3 million prescriptions in the first quarter on the U.S. market and another 1.1 million in the first six weeks of the second quarter. Quigley described the launch speed as unusually rapid, strengthening Novo\u2019s competitive position in obesity care.<\/p>\n